AstraZeneca’s pivot point might not come until 2018
Much will depend on drug trial data readouts in the second half of this year
via Construction http://ift.tt/2p8YAaj
This entry was published on May 2, 2017 at 4:10 pm and is filed under Main
Bookmark the permalink.